There is an ongoing trial with a biclonal anti-IL-1/IL-18 antibody in patients with an NLRC4 gain of function mutation, a rare autoinflammatory disease; such an approach might be also of interest in SJIA patients with MAS. Here, NLRC4 is linked to macrophage activation syndrome.